此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

心血管风险评估和基于动态监测的预防试验 (CRITICALLY)

2026年9月17日 更新者:Pei Gao、Peking University

鄞州基层医疗质量评价心血管风险评估与动态监测预防试验

The CRITICALLY study is a cluster randomized trial that will evaluate the effectiveness of a risk-based dynamic monitoring strategy for the primary prevention of cardiovascular high-risk Chinese adults.

研究概览

详细说明

The objective of the study is to evaluate the effectiveness of a risk-based management strategy on cardiovascular risk scores (calculated by the 2019 WHO cardiovascular risk charts) in 24 months (Phase I) and the incidence of major adverse cardiovascular events in 60 months (Phase II). Totally 216 clinics in Yinzhou District, China will be randomized to the intervention or the control arms with usual care. The interventions supported by the web-based decision support system include (1) cardiovascular risk assessment, (2) dynamic risk monitoring, and (3) regular visits by the general practitioner every three months. Only usual care will be provided in the control arm. The primary outcome is the change in cardiovascular risk scores for Phase I and the incidence of the composite endpoint of coronary heart disease, stroke, heart failure and all-cause mortality for Phase II. If the comprehensive strategy is proven effective, it could provide evidence for the primary prevention of cardiovascular diseases using digital health technology.

研究类型

介入性

注册 (估计的)

22032

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Xun TANG, PhD, MHS
  • 电话号码:+86-10-82801528 ext 317
  • 邮箱:tangxun@bjmu.edu.cn

学习地点

    • Zhejiang
      • Ningbo、Zhejiang、中国、315100
        • 招聘中
        • Yinzhou District Center for Disease Control and Prevention
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 至 79年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Residents in the Yinzhou District have a unique health ID;
  • Aged 40 to 79 years at the baseline enrollment;
  • With high risk of cardiovascular disease evaluated by the 2019 WHO laboratory-based risk models (10-year risk≥10%);

Exclusion Criteria:

  • Have a history of coronary heart disease, stroke or heart failure;
  • Patients with a diagnosis of cancer;
  • Refused to provide written informed consent

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Intervention arm

The interventions include cardiovascular risk assessment, dynamic risk monitoring, and regular general practitioner (GP) visits. The frequency of risk assessment, risk monitoring, and automatic mobile texting will be once per month, while regular GP visits will be once per three months.

The 10-year cardiovascular risk scores using the 2019 World Health Organization (WHO) laboratory-based risk charts will be automatically calculated using the latest health information on an EHR-based system per month.

High-risk individuals will be reassessed by the Dynamic Risk-based Early wArning and Monitoring (DREAM) system to obtain the short-term risk. The DREAM system will send a text message about advice to the high-risk individual every month. The text message includes information on the health status (e.g., current cardiovascular risk, level of blood pressure and lipid) and real-time warning messages (e.g., high short-term risk).

The general practitioners will communicate with the participants based on the information automatically generated from the DREAM system every three months: each participant's cardiovascular risk score, health status (e.g., diabetes mellitus and/or hypertension), and Chinese guidelines-based recommendations (e.g., "for the management of dyslipidemia, to provide clear treatment targets for high-risk participants").

无干预:Control arm

Current regular management (usual care) will be kept in the control arm. The management objectives are for patients with hypertension or diabetes mellitus. The frequency of follow-up is at least once per three months.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Primary Outcome of Phase I: Change in cardiovascular risk score
大体时间:24 months after baseline

The change in cardiovascular risk scores calculated by 2019 WHO laboratory-based risk charts

24 months after baseline
Primary Outcome of Phase II: Major adverse cardiovascular events (MACE)
大体时间:60 months after baseline

Incidence of coronary heart disease, stroke, heart failure and all-cause mortality

60 months after baseline

次要结果测量

结果测量
措施说明
大体时间
Secondary Outcome of Phase I: Change in systolic blood pressure
大体时间:24 months after baseline

the change in systolic blood pressure from baseline

24 months after baseline
Secondary Outcome of Phase I: Change in total cholesterol
大体时间:24 months after baseline

the change in total cholesterol from baseline

24 months after baseline
Secondary Outcome of Phase I: Change in low-density lipoprotein cholesterol
大体时间:24 months after baseline

the change in low-density lipoprotein cholesterol from baseline

24 months after baseline
Secondary Outcome of Phase II: Change in health-related quality of life
大体时间:60 months after baseline

Measured using the EuroQol-5 Dimensions-5L(EQ-5D)

60 months after baseline

其他结果措施

结果测量
措施说明
大体时间
Other Pre-specified Outcome of Phase II: Incremental cost-effectiveness ratio (ICER)
大体时间:60 months after baseline

the incremental cost-effectiveness ratio (ICER) of the management provided by the interventions compared to the usual care

60 months after baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Xun TANG, PhD, MHS
  • 首席研究员:Pei GAO, PhD

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年7月6日

初级完成 (估计的)

2028年7月1日

研究完成 (估计的)

2028年7月1日

研究注册日期

首次提交

2023年6月16日

首先提交符合 QC 标准的

2023年6月16日

首次发布 (实际的)

2023年6月26日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月17日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • IRB00001052-21060

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

According to the Administrative Regulations on Human Genetic Resources issued by the State Council of the People's Republic of China in 2019, we are waiting for the approval of IPD sharing.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅